Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD
Recruiting
N/A
Interventional Study
Alzheimer Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 50 – 90
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 244 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
BioCogBankAD aims at building a prospective clinical practice cohort of 244 patients with biologically confirmed mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD in order to validate data regarding markers of resilience toward AD pathophysiological process discovered in an upstream project called AD-Resilience.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of AD according to IWG-2 2014 criteria
* Age 50-90 year old
* Affiliated or beneficiary of a social security scheme
* MMSE ≥ 20
* Abnormal CSF Aβ42 or Aβ40/Aβ42 ratio according to local cut-offs
* Abnormal CSF phosphorylated and total Tau according to local cut-offs
…
Contacts